# Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia

> **NCT03464682** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 720 (estimated)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HS-25 10mg
- **DRUG:** HS-25 10mg combination with Atorvastatin
- **DRUG:** HS-25 20mg combination with Atorvastatin
- **DRUG:** Atorvastatin 10mg
- **DRUG:** HS-25 20mg
- **DRUG:** Placebe of HS-25 and Atorvastatin

## Key facts

- **NCT ID:** NCT03464682
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02-28
- **Primary completion:** 2018-12-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464682, "Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03464682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*